PSMA radioligand therapy has been successful in prolonging the life and temporarily reducing the tumor burden in terminally ill prostate cancer patients with limited observed toxicity, although it is not curative in metastatic CRPC [5,6,7]. The gene discussed is FOLH1; the disease is prostate carcinoma.